{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Respiratory+Papillomatosis",
    "query": {
      "condition": "Recurrent Respiratory Papillomatosis"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 19,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Respiratory+Papillomatosis&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T09:05:39.093Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00829608",
      "title": "Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Recurrent Respiratory Papillomatosis"
      ],
      "interventions": [
        {
          "name": "Human Papillomavirus Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Missouri-Columbia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2009-01",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2016-10-05",
      "last_synced_at": "2026-05-22T09:05:39.093Z",
      "location_count": 1,
      "location_summary": "Columbia, Missouri",
      "locations": [
        {
          "city": "Columbia",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00829608"
    },
    {
      "nct_id": "NCT06538480",
      "title": "Zopa Retreatment and Vector Shedding in Adults With RRP",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Recurrent Respiratory Papillomatosis",
        "Papillomavirus Infection",
        "Papillomaviridae"
      ],
      "interventions": [
        {
          "name": "Zopapogene imadenovec (Zopa)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Precigen, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2024-07-11",
      "completion_date": "2028-12-02",
      "has_results": false,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-05-22T09:05:39.093Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Bethesda, Maryland • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06538480"
    },
    {
      "nct_id": "NCT00571701",
      "title": "Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Respiratory Papillomatosis"
      ],
      "interventions": [
        {
          "name": "celebrex (celecoxib)",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2008-02",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2017-05-15",
      "last_synced_at": "2026-05-22T09:05:39.093Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Iowa City, Iowa + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        },
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00571701"
    },
    {
      "nct_id": "NCT01020747",
      "title": "Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Respiratory Papillomatosis"
      ],
      "interventions": [
        {
          "name": "Avastin® (bevacizumab)",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 20,
      "start_date": "2009-11",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2012-12-20",
      "last_synced_at": "2026-05-22T09:05:39.093Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01020747"
    },
    {
      "nct_id": "NCT04724980",
      "title": "Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Respiratory Papillomatosis",
        "Papillomavirus Infections",
        "Papillomaviridae"
      ],
      "interventions": [
        {
          "name": "PRGN-2012 - Phase I; Dose Level 1",
          "type": "DRUG"
        },
        {
          "name": "PRGN-2012 - Phase I; Dose Level 2",
          "type": "DRUG"
        },
        {
          "name": "PRGN-2012 - Phase II; Dose Level 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Precigen, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2021-03-16",
      "completion_date": "2026-06-05",
      "has_results": false,
      "last_update_posted_date": "2025-06-11",
      "last_synced_at": "2026-05-22T09:05:39.093Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04724980"
    },
    {
      "nct_id": "NCT02632344",
      "title": "Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Respiratory Papillomatosis"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2016-04",
      "completion_date": "2025-12",
      "has_results": true,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-05-22T09:05:39.093Z",
      "location_count": 2,
      "location_summary": "Evanston, Illinois • Boston, Massachusetts",
      "locations": [
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02632344"
    },
    {
      "nct_id": "NCT05797246",
      "title": "Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Tract Diseases",
        "Neoplasms",
        "Neoplasms by Histologic Type",
        "Neoplasms, Glandular and Epithelial",
        "Neoplasms, Squamous Cell",
        "Tumor Virus Infections",
        "Infections",
        "Virus Diseases",
        "DNA Virus Infections",
        "Pathologic Processes",
        "Disease Attributes",
        "Recurrence",
        "Papilloma",
        "Respiratory Tract Infections",
        "Papillomavirus Infections"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 21,
      "start_date": "2023-08-02",
      "completion_date": "2029-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-07",
      "last_synced_at": "2026-05-22T09:05:39.093Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05797246"
    },
    {
      "nct_id": "NCT00747461",
      "title": "Interventional Cryotherapy for the Eradication of Benign Airway Disease (\"ICE the BAD\")",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Lung Diseases, Obstructive",
        "Sarcoidosis",
        "Wegener's Granulomatosis",
        "Rhinoscleroma",
        "Recurrent Respiratory Papillomatosis"
      ],
      "interventions": [
        {
          "name": "CryoSpray Ablation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "CSA Medical, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2008-10",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2015-08-18",
      "last_synced_at": "2026-05-22T09:05:39.093Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00747461"
    },
    {
      "nct_id": "NCT04645602",
      "title": "Merck IIT: RRP Pembro and Lenvatinib",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Human Papilloma Virus",
        "Recurrent Respiratory Papillomatosis",
        "Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-07-18",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-05-22T09:05:39.093Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04645602"
    },
    {
      "nct_id": "NCT00038714",
      "title": "A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory Papillomatosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Papilloma",
        "Recurrent Respiratory Papillomatosis"
      ],
      "interventions": [
        {
          "name": "SGN-00101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nventa Biopharmaceuticals Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 27,
      "start_date": "2001-11",
      "completion_date": "2004-01",
      "has_results": false,
      "last_update_posted_date": "2007-06-27",
      "last_synced_at": "2026-05-22T09:05:39.093Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Jacksonville, Florida + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00038714"
    }
  ]
}